The efficacy of Mecapegfilgrastim therapy in the primary prevention of concurrent chemoradiotherapy-induced neutropenia

Abstract

ObjectiveTo evaluate the efficacy and safety of mecapegfilgrastim therapy in primary prevention of neutropenia after concurrent chemoradiotherapy for cervical cancer. MethodsThis study was a single-center, open, one-arm clinical observation, and analyzed the effectiveness of mecapegfilgrastim primary prevention of neutropenia after concurrent chemoradiotherapy in 25 cervical cancer patients undergoing concurrent chemoradiotherapy in Tianjin Medical University Cancer Institute and Hospital from 2019 to 2021. ResultsDuring the whole concurrent chemorrhotic cycle, chemotherapy delay occurred in 8 patients, (16%). The completion rate of chemotherapy cycle was 84% (42/50). There were only 4 (8%) cases of delayed concurrent chemotherapy due to leukopenia or neutropenia. Radiotherapy delay occurred in 10 patients, (20%). None of the patients delayed radiotherapy due to leukopenia or neutropenia. The incidence of febrile neutropenia (FN) was 0%. Subgroup analysis found that after completing 1 cycle of concurrent chemoradiotherapy, 6(12%) patients with grade 3–4 leukocyte or neutropenia. After completing 2 cycles of concurrent chemoradiotherapy, 14(29%) patients with grade 3–4 leukocyte or neutropenia. ConclusionDuring the chemoradiation in patients with cervical cancer, primary prevention use of mecapegfilgrastim can significantly reduce the incidence of FN, effectively reduce the incidence of grade III-Ⅳ leukopenia or neutropenia, beneficial to ensure the smooth progress of concurrent chemoradiotherapy,and provide a new direction for primary prevention of cervical cancer chemotherapy.